User profiles for Alexandra Stege
 | Alexandra StegeCharité - Universitätsmedizin Berlin Verified email at charite.de Cited by 939 |
[HTML][HTML] Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi)
C Nieth, A Priebsch, A Stege, H Lage - FEBS letters, 2003 - Elsevier
For reversal of MDR1 gene-dependent multidrug resistance (MDR), two small interfering
RNA (siRNA) constructs were designed to inhibit MDR1 expression by RNA interference. …
RNA (siRNA) constructs were designed to inhibit MDR1 expression by RNA interference. …
Towards a unification of treatments and interventions for tinnitus patients: The EU research and innovation action UNITI
…, B Boecking, N Amarjargal, S Specht, A Stege… - Progress in brain …, 2021 - Elsevier
Tinnitus is the perception of a phantom sound and the patient's reaction to it. Although much
progress has been made, tinnitus remains a scientific and clinical enigma of high …
progress has been made, tinnitus remains a scientific and clinical enigma of high …
Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference
A Stege, A Priebsch, C Nieth, H Lage - Cancer Gene Therapy, 2004 - nature.com
Multidrug resistance (MDR) is the major cause of failure of effective chemotherapeutic treatment
of disseminated neoplasms. The “classical” MDR phenotype of human malignancies is …
of disseminated neoplasms. The “classical” MDR phenotype of human malignancies is …
RNA interference-triggered reversal of ABCC2-dependent cisplatin resistance in human cancer cells
V Materna, A Stege, P Surowiak, A Priebsch… - … and biophysical research …, 2006 - Elsevier
The adenosine triphosphate binding cassette (ABC)-transporter ABCC2 (MRP2/cMOAT)
can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. …
can mediate resistance against the commonly used anticancer drugs cisplatin and paclitaxel. …
Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study …
…, CEP Goldring, O Poetz, R Lombaard, A Stege… - … and prognostic research, 2023 - Springer
A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder
early- and late-stage drug development and remains a challenge in clinical practice. The …
early- and late-stage drug development and remains a challenge in clinical practice. The …
Complete in vivo reversal of the multidrug resistance phenotype by jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA
U Stein, W Walther, A Stege, A Kaszubiak, I Fichtner… - Molecular Therapy, 2008 - cell.com
Triggering the RNA interference (RNAi) pathway by inducing the expression of short hairpin
RNA (shRNA) molecules has become a promising tool for efficient silencing of a given gene …
RNA (shRNA) molecules has become a promising tool for efficient silencing of a given gene …
Unification of Treatments and Interventions for Tinnitus Patients (UNITI): a study protocol for a multi-center randomized clinical trial
Background Tinnitus represents a relatively common condition in the global population
accompanied by various comorbidities and severe burden in many cases. Nevertheless, there is …
accompanied by various comorbidities and severe burden in many cases. Nevertheless, there is …
Glypican-3 is involved in cellular protection against mitoxantrone in gastric carcinoma cells
A Wichert, A Stege, Y Midorikawa, PS Holm, H Lage - Oncogene, 2004 - nature.com
Elevated expression of the heparan sulphate proteoglycan glypican-3 (GPC3) was found on
mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line …
mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line …
Complete reversal of ABCG2-depending atypical multidrug resistance by RNA interference in human carcinoma cells
…, H Tönnies, P Kowalski, P Surowiak, A Stege… - …, 2006 - liebertpub.com
In the chemotherapeutic treatment of patients with disseminated neoplasms, multidrug
resistance (MDR) is a major obstacle. ABCG2 (BCRP/MXR), a member of the superfamily of …
resistance (MDR) is a major obstacle. ABCG2 (BCRP/MXR), a member of the superfamily of …
Overcoming multidrug resistance by RNA interference
A Stege, A Krühn, H Lage - Multi-drug resistance in cancer, 2010 - Springer
The ATP-binding cassette (ABC)-transporter P-glycoprotein (Pgp, also known as ABCB1) is
the best characterized factor involved in multidrug resistance (MDR) of cancer cells. Pgp, …
the best characterized factor involved in multidrug resistance (MDR) of cancer cells. Pgp, …
